Suitability of a High-energy, Low-protein Formula (Renalive® LP)
- CKD
- Low Protein Dietary Intake
- Malnutrition (Calorie)
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- Fresenius Kabi Taiwan Ltd.
- Enrolment target
- 80
- Started
- 4 June 2025
- Main results due
- 31 December 2027
- Study sites
- 2
- Registry updated
- 28 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: (1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR\<45 mL/min/1.73 m2) Exclusion Criteria: (1) Has received dialysis or are expected to start dialysis within the next 3 months
What this study is about
In the sponsor’s own words, from the registry.
Inclusion criteria (1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR\<45 mL/min/1.73 m2)
Exclusion criteria
(1) Has received dialysis or are expected to start dialysis within the next 3 months.
Study sites(2)
Kaosiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
Recruiting
Taipei TzuChi Hospital
New Taipei City, Taiwan
Recruiting
Showing 2 of 2 sites. 2 of the 2 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06892249. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me